UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State |
(Commission |
(I.R.S. Employer | ||
of incorporation) | File Number) | Identification Number) |
(Address of principal executive offices) (Zip code) | ||
(Registrant’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
Eton announced that the U.S. Food and Drug Administration (FDA) has approved ZONISADE™ (zonisamide oral suspension). ZONISADE™ was included in Eton’s multi-product neurology oral solution partnership with Azurity Pharmaceuticals announced in February of 2021. Under the agreement, Eton is entitled to receive an additional $5 million payment upon the launch of ZONISADE™, royalty on net sales, and up to $15 million of commercial milestones tied to the combined sales of all three products in the partnership. Azurity Pharmaceuticals will be responsible for the commercialization of ZONISADE™, and no marketing expenses will be incurred by Eton.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 18, 2022 | By: | /s/ James Gruber |
James Gruber | ||
Chief Financial Officer and Secretary | ||
(Principal Financial Officer) |
3 |
Cover |
Jul. 18, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 18, 2022 |
Entity File Number | 001-38738 |
Entity Registrant Name | ETON PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001710340 |
Entity Tax Identification Number | 37-1858472 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 21925 W. Field Parkway |
Entity Address, Address Line Two | Suite 235 |
Entity Address, City or Town | Deer Park |
Entity Address, State or Province | IL |
Entity Address, Postal Zip Code | 60010-7208 |
City Area Code | (847) 787-7361 |
Local Phone Number | 787-7361 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | ETON |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | true |
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end
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end